| scholarly article | Q13442814 |
| P50 | author | John C. Byrd | Q66429603 |
| P2093 | author name string | David M Lucas | |
| Yanhui Lu | |||
| David Jarjoura | |||
| Amy Lehman | |||
| Rosa Lapalombella | |||
| Erin Hertlein | |||
| Jennifer A Woyach | |||
| Timothy L Chen | |||
| Sneha V Gupta | |||
| Ellen J Sass | |||
| Melanie E Davis | |||
| P2860 | cites work | Discovery of a potent, selective, and orally active proteasome inhibitor for the treatment of cancer | Q40016892 |
| Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells | Q40310345 | ||
| Proteasome-dependent regulation of p21WAF1/CIP1 expression | Q41158898 | ||
| Role of NOXA and its ubiquitination in proteasome inhibitor-induced apoptosis in chronic lymphocytic leukemia cells | Q41915878 | ||
| Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach | Q42191925 | ||
| Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids | Q42537232 | ||
| Approval summary for bortezomib for injection in the treatment of multiple myeloma | Q44951957 | ||
| Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome | Q46119731 | ||
| Bortezomib or high-dose dexamethasone for relapsed multiple myeloma | Q46549268 | ||
| The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status | Q46706369 | ||
| Association of germline or somatic TP53 missense mutation with oncogene amplification in tumors developed in patients with Li-Fraumeni or Li-Fraumeni-like syndrome. | Q54378331 | ||
| p53-dependent induction of apoptosis by proteasome inhibitors | Q73334980 | ||
| CD95 (Fas)-induced caspase-mediated proteolysis of NF-kappaB | Q74309691 | ||
| Gene expression profiling of the functionally distinct human bone marrow stromal cell lines HS-5 and HS-27a | Q74622430 | ||
| p53 downstream target genes and tumor suppression: a classical view in evolution | Q79306638 | ||
| Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate | Q82458556 | ||
| Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia | Q84179360 | ||
| TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations | Q85068912 | ||
| The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction | Q24292709 | ||
| The NF-kappa B and I kappa B proteins: new discoveries and insights | Q24313579 | ||
| Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines | Q24616084 | ||
| Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions | Q27824806 | ||
| Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia: results from a detailed genetic characterization with long-term follow-up | Q27851444 | ||
| The ubiquitin-proteasome pathway and proteasome inhibitors | Q28367002 | ||
| Ubiquitin signalling in the NF-kappaB pathway | Q29616322 | ||
| Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27 | Q29617346 | ||
| Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies | Q33345317 | ||
| Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia | Q33371900 | ||
| A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies | Q33387006 | ||
| A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma | Q33401596 | ||
| A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma | Q33402536 | ||
| Phosphoinositide 3-kinase signalling pathways | Q33940898 | ||
| The ups and downs of p53: understanding protein dynamics in single cells | Q33941653 | ||
| Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm | Q34060474 | ||
| Ubiquitin-mediated proteolysis of vertebrate G1- and S-phase regulators | Q34176430 | ||
| Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals | Q34184717 | ||
| The novel cyclin-dependent kinase inhibitor dinaciclib (SCH727965) promotes apoptosis and abrogates microenvironmental cytokine protection in chronic lymphocytic leukemia cells | Q34287781 | ||
| An open-label, single-arm, phase 2 study of single-agent carfilzomib in patients with relapsed and/or refractory multiple myeloma who have been previously treated with bortezomib | Q34291281 | ||
| Bortezomib induces nuclear translocation of IκBα resulting in gene-specific suppression of NF-κB--dependent transcription and induction of apoptosis in CTCL. | Q34802998 | ||
| The BCL-2 family reunion | Q35568029 | ||
| Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia. | Q36085962 | ||
| Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma | Q36384889 | ||
| The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance | Q37152481 | ||
| Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells | Q37291635 | ||
| Signalling to drug resistance in CLL. | Q37771671 | ||
| Novel proteasome inhibitors to overcome bortezomib resistance | Q37878771 | ||
| Carfilzomib-dependent selective inhibition of the chymotrypsin-like activity of the proteasome leads to antitumor activity in Waldenstrom's Macroglobulinemia. | Q39585342 | ||
| Activation of human B cells by phosphorothioate oligodeoxynucleotides | Q39770135 | ||
| Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome | Q39813739 | ||
| Dietary flavonoids inhibit the anticancer effects of the proteasome inhibitor bortezomib | Q39960462 | ||
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | chronic lymphocytic leukemia | Q1088156 |
| NF-κB | Q411114 | ||
| lymphocyte | Q715347 | ||
| P304 | page(s) | 2406-2419 | |
| P577 | publication date | 2013-03-20 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | The proteasome inhibitor carfilzomib functions independently of p53 to induce cytotoxicity and an atypical NF-κB response in chronic lymphocytic leukemia cells | |
| P478 | volume | 19 |
| Q38187815 | Apoptosis inducers in chronic lymphocytic leukemia |
| Q38124119 | B-cell antigen receptor signaling in chronic lymphocytic leukemia: therapeutic targets and translational opportunities |
| Q38882194 | Bortezomib and Arsenic Trioxide Activity on a Myelodysplastic Cell Line (P39): A Gene Expression Study. |
| Q37427124 | Carfilzomib Triggers Cell Death in Chronic Lymphocytic Leukemia by Inducing Proapoptotic and Endoplasmic Reticulum Stress Responses |
| Q26764833 | Chronic Lymphocytic Leukemia: Exploiting Vulnerabilities with Targeted Agents |
| Q90638896 | Evidence for the Involvement of the Master Transcription Factor NF-κB in Cancer Initiation and Progression |
| Q26781895 | Know the enemy as well as the weapons in hand: the aberrant death pathways and therapeutic agents in chronic lymphocytic leukemia |
| Q34038263 | MCPIP1 contributes to the toxicity of proteasome inhibitor MG-132 in HeLa cells by the inhibition of NF-κB |
| Q39036088 | PI3KCA plays a major role in multiple myeloma and its inhibition with BYL719 decreases proliferation, synergizes with other therapies and overcomes stroma-induced resistance. |
| Q33420278 | Phase I dose escalation trial of the novel proteasome inhibitor carfilzomib in patients with relapsed chronic lymphocytic leukemia and small lymphocytic lymphoma |
| Q52370139 | Proteasome inhibition blocks necroptosis by attenuating death complex aggregation. |
| Q43096794 | Proteasome inhibitor carfilzomib complements ibrutinib's action in chronic lymphocytic leukemia |
| Q37689041 | Second-generation proteasome inhibitor carfilzomib sensitizes neuroblastoma cells to doxorubicin-induced apoptosis |
| Q58779410 | Synergistic combination of flavopiridol and carfilzomib targets commonly dysregulated pathways in adrenocortical carcinoma and has biomarkers of response |
| Q37430243 | Targeted therapy in chronic lymphocytic leukemia: past, present, and future |
| Q37564440 | The isopeptidase inhibitor 2cPE triggers proteotoxic stress and ATM activation in chronic lymphocytic leukemia cells |
| Q28392681 | The novel proteasome inhibitor carfilzomib activates and enhances extrinsic apoptosis involving stabilization of death receptor 5 |
| Q34566295 | Tumor necrosis factor-α sensitizes breast cancer cells to natural products with proteasome-inhibitory activity leading to apoptosis |
Search more.